Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Emergent BioSolutions Inc. Common Stock (NY:EBS)

11.03 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EST, Feb 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Emergent BioSolutions Inc. Common Stock

< Previous 1 2 3 4 5 6 Next >
News headline image
Emergent BioSolutions Awarded Procurement Contract Valued up to $235.8 Million to Supply BioThrax® (Anthrax Vaccine Adsorbed) to the U.S. Department of Defense
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 11, 2024
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions Receives $75 Million Contract Option from BARDA to Procure Doses of CYFENDUS™ (Anthrax Vaccine Adsorbed, Adjuvanted)
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions Receives NYSE Notice Regarding Delayed Form 10-Q Filing
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions Reports Third Quarter 2023 Financial Results
From Emergent BioSolutions
Via GlobeNewswire
News headline image
UPDATE: Emergent BioSolutions to Release Third Quarter 2023 Financial Results and Conduct Conference Call on November 8, 2023
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions to Release Third Quarter 2023 Financial Results and Conduct Conference Call on November 2, 2023
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions Names Two Pharmaceutical Industry Veterans to Board of Directors
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions’ NARCAN® Nasal Spray Launches Over the Counter Making it Possible for Everyone to Help Save a Life from an Opioid Overdose Emergency
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions Reports Financial Results for Second Quarter 2023
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions Announces Strategic Steps to Strengthen Core Business and Financial Position
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions Awarded 10-Year BARDA Contract Valued at up to a Maximum of $704 Million for Advanced Development and Procurement of Ebanga™ Treatment for Ebola
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions to Release Second Quarter 2023 Financial Results and Conduct Conference Call on August 8, 2023
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions Receives U.S. FDA Approval of CYFENDUS™ (Anthrax Vaccine Adsorbed, Adjuvanted), previously known as AV7909, a Two-Dose Anthrax Vaccine for Post-Exposure Prophylaxis Use
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions Announces CEO Transition
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions Finalizes Sale of Travel Health Business to Bavarian Nordic
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions to Hold Virtual Annual Meeting of Stockholders on Thursday, May 25, 2023 at 9:00am EDT
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions Reports Financial Results For First Quarter 2023
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions to Release First Quarter 2023 Financial Results and Conduct Conference Call on May 9, 2023
From Emergent BioSolutions
Via GlobeNewswire
News headline image
U.S. FDA Approves Over-the-Counter Designation for Emergent BioSolutions’ NARCAN® Nasal Spray, a Historic Milestone for the Opioid Overdose Emergency Treatment
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions Reports Financial Results for Fourth Quarter 2022
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions Reports FDA Advisory Committees’ Unanimous Vote in Favor of NARCAN® (naloxone HCI) Nasal Spray for Over-the-Counter Use
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions Announces Sale of Travel Health Business to Bavarian Nordic for Up To $380 Million
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions to Release Fourth Quarter 2022 Financial Results and Conduct Conference Call on February 27, 2023
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Johnson & Johnson Breakout Breaks Down: Can Earnings Boost Stock?
Johnson & Johnson stock has been struggling to break out of a correction. It formed a cup-shaped pattern that appeared to add a handle but broke down last week. 
Via MarketBeat
Topics Stocks
News headline image
Emergent BioSolutions Announces Organizational Changes as Part of Sharpened Strategic Focus
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions Awarded $379.6 Million Procurement Contract to Supply RSDL© (Reactive Skin Decontamination Lotion Kit) to U.S. Department of Defense
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions Announces U.S. FDA Acceptance and Priority Review of Supplemental New Drug Application for Over-the-Counter NARCAN® (naloxone HCl) Nasal Spray
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions Receives Department of Defense Award to Evaluate Chikungunya Vaccine Candidate in Post-Approval Field Efficacy Study Using Model-Guided Approach
Emergent partners with the Armed Forces Research Institute of Medical Sciences for its capabilities in Chikungunya virus surveillance and field studies 
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions Reports Financial Results For Third Quarter 2022
From Emergent BioSolutions
Via GlobeNewswire
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.